Patient Receives First Genetically Engineered Phage Treatment

A pediatric patient with cystic fibrosis and a double-lung transplant received a genetically engineered 3-phage cocktail to treat a life-threatening antibiotic-resistant Mycobacterium abscessus infection for which all standard therapeutic options had been exhausted. Over 7 months of twice-daily intravenous infusions, as well as daily topical phage therapy, the 15-year-old patient ’s surgical wound and skin lesions healed gradually and her lung and liver function improved. No adverse reactions to the treatment were reported.
Source: JAMA - Category: General Medicine Source Type: research